UK markets close in 6 hours 6 minutes
  • FTSE 100

    7,018.01
    -91.94 (-1.29%)
     
  • FTSE 250

    22,501.44
    -254.89 (-1.12%)
     
  • AIM

    1,183.80
    -6.71 (-0.56%)
     
  • GBP/EUR

    1.1759
    -0.0024 (-0.20%)
     
  • GBP/USD

    1.3359
    +0.0047 (+0.35%)
     
  • BTC-GBP

    42,445.39
    -531.94 (-1.24%)
     
  • CMC Crypto 200

    1,434.65
    +5.72 (+0.40%)
     
  • S&P 500

    4,655.27
    +60.65 (+1.32%)
     
  • DOW

    35,135.94
    +236.60 (+0.68%)
     
  • CRUDE OIL

    68.29
    -1.66 (-2.37%)
     
  • GOLD FUTURES

    1,798.20
    +13.00 (+0.73%)
     
  • NIKKEI 225

    27,821.76
    -462.16 (-1.63%)
     
  • HANG SENG

    23,475.26
    -376.98 (-1.58%)
     
  • DAX

    15,070.20
    -210.66 (-1.38%)
     
  • CAC 40

    6,687.21
    -89.04 (-1.31%)
     

Insights on the Menopause Global Market to 2026 - Featuring Abbvie, Allergan and Bayer Among Others

·7-min read

Dublin, Nov. 04, 2021 (GLOBE NEWSWIRE) -- The "Menopause Market Research Report by Treatment, Distribution Challenge, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Menopause Market size was estimated at USD 14.71 billion in 2020, is expected to reach USD 15.64 billion in 2021, and projected to grow at a CAGR of 6.65% reaching USD 21.66 billion by 2026.

Market Statistics

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage

This research report categorizes the Menopause to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Treatment, the market was studied across Dietary Supplements and OTC Pharma Products. The OTC Pharma Products is further studied across Hormonal products and Non-hormonal products.

  • Based on Distribution Challenge, the market was studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.

  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Competitive Strategic Window

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Menopause Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Menopause Market, including Abbvie Inc., Allergan plc, Bayer AG, Cipla Inc., Eli Lilly and Company, Emcure Pharmaceuticals Ltd., GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Merck & Co.Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and TherapeuticsMD Inc.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Menopause Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Menopause Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Menopause Market?
4. What is the competitive strategic window for opportunities in the Global Menopause Market?
5. What are the technology trends and regulatory frameworks in the Global Menopause Market?
6. What is the market share of the leading vendors in the Global Menopause Market?
7. What modes and strategic moves are considered suitable for entering the Global Menopause Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. High prevalence of vasomotor and other menopausal symptoms
5.2.2. Rising awareness regarding menopause health
5.2.3. Increasing number of new drug approvals for the treatment
5.3. Restraints
5.3.1. Side effects associated with hormonal products and the availability of generic medicines
5.4. Opportunities
5.4.1. Prevalence of herbal treatment for menopause
5.4.2. Increasing research supporting the advantages of dietary supplements
5.5. Challenges
5.5.1. Lack of advanced healthcare infrastructure

6. Menopause Market, by Treatment
6.1. Introduction
6.2. Dietary Supplements
6.3. OTC Pharma Products
6.3.1. Hormonal products
6.3.2. Non-hormonal products

7. Menopause Market, by Distribution Challenge
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Stores
7.4. Retail Pharmacies

8. Americas Menopause Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Menopause Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand

10. Europe, Middle East & Africa Menopause Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, by Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbvie Inc.
12.2. Allergan plc
12.3. Bayer AG
12.4. Cipla Inc.
12.5. Eli Lilly and Company
12.6. Emcure Pharmaceuticals Ltd.
12.7. GlaxoSmithKline plc
12.8. Glenmark Pharmaceuticals Ltd.
12.9. Hisamitsu Pharmaceutical Co. Inc.
12.10. Merck & Co.Inc.
12.11. Novartis AG
12.12. Novo Nordisk A/S
12.13. Pfizer Inc.
12.14. Teva Pharmaceutical Industries Ltd.
12.15. TherapeuticsMD Inc.

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/a72d5m

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting